Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat


Tytuł :
Resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis associated with rapid immune reconstruction after a single course of CHOP therapy.
Autorzy :
Chikagawa Y; Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.; Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Hikishima K; Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.
Mizumaki H; Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.; Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa, Ishikawa, Japan.
Sugimori C; Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.
Nakagishi Y; Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
Yachie A; Division of Medical Safety, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Nakao S; Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa, Ishikawa, Japan. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 889-893. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Herpesvirus 4, Human*/immunology
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphohistiocytosis, Hemophagocytic/*drug therapy
Lymphohistiocytosis, Hemophagocytic/*immunology
Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; CD8-Positive T-Lymphocytes/immunology ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/pharmacology ; Doxorubicin/administration & dosage ; Doxorubicin/pharmacology ; Female ; Humans ; Lymphohistiocytosis, Hemophagocytic/virology ; Prednisolone/administration & dosage ; Prednisolone/pharmacology ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/pharmacology ; Viral Load/drug effects
SCR Protocol :
VAP-cyclo protocol
Czasopismo naukowe
Tytuł :
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Autorzy :
Matsuda S; Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Suzuki R; Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Takahashi T; Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Suehiro Y; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Tomita N; Department of Hematology, St. Marianna University School of Medicine, Kawasaki, Japan.
Izutsu K; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Fukuhara N; Department of Hematology, Tohoku University Hospital, Sendai, Japan.
Imaizumi Y; Department of Hematology, Nagasaki University, Nagasaki, Japan.
Shimada K; Department of Hematology, Nagoya University Hospital, Nagoya, Japan.
Nakazato T; Department of Hematology, Yokohama Municipal Citizens Hospital, Yokohama, Japan.
Yoshida I; Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Miyazaki K; Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Yamaguchi M; Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Suzumiya J; Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 807-816. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma/*drug therapy
Rituximab/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Communicable Diseases/epidemiology ; Communicable Diseases/etiology ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Feasibility Studies ; Febrile Neutropenia/epidemiology ; Febrile Neutropenia/etiology ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Young Adult
SCR Protocol :
EPOCH protocol
Czasopismo naukowe
Tytuł :
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Autorzy :
Tacchetti P; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pantani L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Patriarca F; Clinical Hematology and Bone Marrow Transplant Centre, S Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy.
Petrucci MT; Hematology Unit, and Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Zamagni E; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Dozza L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Galli M; Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Di Raimondo F; Division of Hematology, Azienda Ospedaliero-Universitaria Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Crippa C; Unità Operativa Complessa di Ematologia, Spedali Civili Brescia, Brescia, Italy.
Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Cittàdella Salute e della Scienza, Turin, Italy.
Barbato S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Tosi P; Unità Operativa, Ematologia, Ospedale Infermi di Rimini, Rimini, Italy.
Narni F; Programma Trapianti Cellule Staminali Emopoietiche, Università di Modena e Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy.
Montefusco V; Department of Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Testoni N; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Spadano A; Unità Operativa Complessa, Ematologia Clinica, Azienda Sanitaria Locale di Pescara, Pescara, Italy.
Terragna C; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pescosta N; Reparto di Ematologia e Centro Trapianto Midollo Osseo, Ospedale Centrale, Bolzano, Italy.
Marzocchi G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Cellini C; Unità Operativa Complessa Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Galieni P; Unità Operativa Complessa Ematologia e Terapia cellulare, Ospedale Costanzo e Giacomo Mazzoni, Ascoli Piceno, Italy.
Ronconi S; IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Gobbi M; Dipartimento di Medicina interna, Clinica Ematologica, Policlinico Ospedale San Martino, Genoa, Italy.
Catalano L; Unità Operativa Ematologia, Azienda Ospedaliero-Universitaria Federico II, Napoli, Italy.
Lazzaro A; Division of Hematology and Bone Marrow Transplant Center, Department of Oncology-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
De Sabbata G; Struttura Complessa Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
Cangialosi C; Divisione di Ematologia ad indirizzo oncologico con Trapianto, Azienda Ospedali Riuniti 'Villa Sofia Cervello', Presidio Ospedaliero 'V Cervello', Palermo, Italy.
Ciambelli F; Struttura Complessa di Ematologia, Azienda Socio Sanitaria Territoriale della Valle Olona, Busto Arsizio, Italy.
Musto P; 'Aldo Moro' University School of Medicine, Unit of Hematology and Stem Cell Transplantation, AOUCPoliclinico, Bari, Italy; Unit of Hematology and Stem Cell Transplantation, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Elice F; Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Cavo M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy. Electronic address: .
Pokaż więcej
Corporate Authors :
GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network)
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Dec; Vol. 7 (12), pp. e861-e873.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bortezomib/*therapeutic use
Dexamethasone/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Multiple Myeloma/*drug therapy
Multiple Myeloma/*therapy
Thalidomide/*therapeutic use
Transplantation Conditioning/*methods
Transplantation, Autologous/*methods
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Thalidomide/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Autorzy :
Durie BGM; Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kumar SK; Mayo Clinic, Rochester, Minnesota, USA.
Usmani SZ; Atrium Health, Charlotte, North Carolina, USA.
Nonyane BAS; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Ammann EM; Janssen Scientific Affairs, Horsham, Pennsylvania, USA.
Lam A; Janssen Global Services, Raritan, New Jersey, USA.
Kobos R; Janssen Research & Development, Raritan, New Jersey, USA.
Maiese EM; Janssen Scientific Affairs, Horsham, Pennsylvania, USA.
Facon T; Department of Haematology, Lille University Hospital, Lille, France.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1486-1494. Date of Electronic Publication: 2020 Sep 05.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Multiple Myeloma/*drug therapy
Multiple Myeloma/*mortality
Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Survival Rate
Czasopismo naukowe
Tytuł :
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Autorzy :
Sonpavde G; Dana-Farber Cancer Institute, Boston, Massachusetts.
Manitz J; EMD Serono, Inc., Billerica, Massachusetts.
Gao C; AstraZeneca, Gaithersburg, Maryland.
Tayama D; Genentech, South San Francisco, California.
Kaiser C; Genentech, South San Francisco, California.
Hennessy D; EMD Serono, Inc., Billerica, Massachusetts.
Makari D; AstraZeneca, Gaithersburg, Maryland.
Gupta A; AstraZeneca, Gaithersburg, Maryland.
Abdullah SE; AstraZeneca, Gaithersburg, Maryland.
Niegisch G; Department of Urology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Rosenberg JE; Memorial Sloan Kettering Cancer Center, New York, New York.
Bajorin DF; Memorial Sloan Kettering Cancer Center, New York, New York.
Grivas P; University of Washington, Seattle, Washington.
Apolo AB; National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Dreicer R; University of Virginia, Charlottesville, Virginia.
Hahn NM; Johns Hopkins University School of Medicine, Baltimore, Maryland.
Galsky MD; Department of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York.
Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Srinivas S; Stanford University Medical Center, Palo Alto, California.
Powles T; Royal Free Hospital, London, United Kingdom.
Choueiri TK; Dana-Farber Cancer Institute, Boston, Massachusetts.
Pond GR; McMaster University, Hamilton, Ontario.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 Dec; Vol. 204 (6), pp. 1173-1179. Date of Electronic Publication: 2020 Jun 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Nomograms*
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Transitional Cell/*drug therapy
Urologic Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carboplatin/pharmacology ; Carboplatin/therapeutic use ; Carcinoma, Transitional Cell/mortality ; Carcinoma, Transitional Cell/secondary ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Datasets as Topic ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Risk Assessment/methods ; Time Factors ; Urologic Neoplasms/mortality ; Urologic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy :
Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Autorzy :
Saygin C; Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Larkin K; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Blachly JS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Orwick S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ngankeu A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Gregory CT; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Phelps MA; Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Mani S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Walker A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Garzon R; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Vasu S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Walsh KJ; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Bhatnagar B; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Klisovic RB; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Grever MR; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Marcucci G; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California.
Byrd JC; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Blum W; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Mims AS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1457-1465. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/mortality
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Female ; Humans ; Idarubicin/administration & dosage ; Idarubicin/adverse effects ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Autorzy :
Morsia E; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
McCullough K; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Joshi M; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Cook J; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Alkhateeb HB; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Al-Kali A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Begna K; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Elliott M; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Hogan W; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Litzow M; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Shah M; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Pardanani A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Patnaik M; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Tefferi A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Gangat N; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1511-1521. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/mortality
Mutation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Neoplasm Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Survival Rate
Czasopismo naukowe
Tytuł :
Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
Autorzy :
Shin W; Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
Noh JJ; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Seo SS; Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
Kang S; Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.; Precision Medicine Branch, National Cancer Center, Goyang, Korea.; Department of Cancer Control & Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Choi CH; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park SY; Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.; Common Cancer Branch, Research Institute, National Cancer Center, Goyang, Korea.
Kim BG; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lim MC; Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.; Department of Cancer Control & Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.; Center for Clinical Trials, Hospital, National Cancer Center, Goyang, Korea.; Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Korea. .
Pokaż więcej
Źródło :
Yonsei medical journal [Yonsei Med J] 2020 Nov; Vol. 61 (11), pp. 935-941.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cytoreduction Surgical Procedures/*adverse effects
Neoadjuvant Therapy/*adverse effects
Ovarian Neoplasms/*therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/pathology ; Cytoreduction Surgical Procedures/mortality ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy/mortality ; Neoplasm Staging ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Autorzy :
Provencio M; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. Electronic address: .
Nadal E; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Insa A; Fundación INCLIVA, Hospital Clínico Universitario de Valencia, Valencia, Spain.
García-Campelo MR; Hospital Universitario A Coruña, A Coruña, Spain.
Casal-Rubio J; Hospital Universitario de Vigo, Pontevedra, Spain.
Dómine M; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Majem M; Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Rodríguez-Abreu D; Hospital Insular de Gran Canaria, Las Palmas, Spain.
Martínez-Martí A; Hospital Universitario e Instituto de Oncología Vall d'Hebron (VHIO), Barcelona, Spain.
De Castro Carpeño J; Hospital Universitario La Paz, Madrid, Spain.
Cobo M; Hospital Universitario Regional de Málaga, Málaga, Spain.
López Vivanco G; Hospital Universitario Cruces, Barakaldo, Spain.
Del Barco E; Hospital Universitario de Salamanca, Salamanca, Spain.
Bernabé Caro R; Hospital Universitario Virgen del Rocio, Seville, Spain.
Viñolas N; Hospital Clínic de Barcelona, Barcelona, Spain.
Barneto Aranda I; Hospital Universitario Reina Sofia, Córdoba, Spain.
Viteri S; Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus-Grupo Quironsalud, Barcelona, Spain.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Royuela A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Casarrubios M; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Salas Antón C; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wistuba I; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Calvo V; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Laza-Briviesca R; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Romero A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Massuti B; Hospital General de Alicante, Alicante, Spain.
Cruz-Bermúdez A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1413-1422. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carboplatin/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Nivolumab/*administration & dosage
Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carboplatin/adverse effects ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Nivolumab/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Spain/epidemiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.
Autorzy :
Tanaka N; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Imai Y; Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. .
Yoshinaga K; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Shiseki M; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Tanaka J; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2577-2586. Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*mortality
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Comorbidity ; Disease-Free Survival ; Etoposide/administration & dosage ; Female ; Humans ; Ifosfamide/administration & dosage ; Male ; Middle Aged ; Rituximab/administration & dosage ; Survival Rate
Czasopismo naukowe
Tytuł :
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Autorzy :
Takezako N; National Hospital Organization Disaster Medical Center, 3256 Midori, Tachikawa, Tokyo, Japan. .
Kosugi H; Ogaki Municipal Hospital, Ogaki, Japan.
Matsumoto M; National Hospital Organization, Shibukawa Medical Center, Shibukawa, Japan.
Iida S; Nagoya City University Hospital, Nagoya, Japan.
Ishikawa T; Kobe City Medical Center, Kobe, Japan.
Kondo Y; Kanazawa University Hospital, Kanazawa, Japan.
Ando K; Tokai University School of Medicine, Isehara, Japan.
Miki H; Tokushima University Hospital, Tokushima, Japan.
Matsumura I; Kindai University Hospital, Osaka-Sayama, Japan.
Sunami K; National Hospital Organization Okayama Medical Center, Okayama, Japan.
Teshima T; Hokkaido University Hospital, Sapporo, Japan.
Iwasaki H; National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Onishi Y; Tohoku University Hospital, Sendai, Japan.
Kizaki M; Saitama Medical Center, Saitama Medical University, Kawagoe-shi, Japan.
Izutsu K; National Cancer Center Hospital, Tokyo, Japan.
Maruyama D; National Cancer Center Hospital, Tokyo, Japan.
Tobinai K; National Cancer Center Hospital, Tokyo, Japan.
Ghori R; Merck & Co., Inc., Kentilworth, NJ, USA.
Farooqui M; Merck & Co., Inc., Kentilworth, NJ, USA.
Liao J; Merck & Co., Inc., Kentilworth, NJ, USA.
Marinello P; Merck & Co., Inc., Kentilworth, NJ, USA.
Matsuda K; MSD K.K, Tokyo, Japan.
Koh Y; MSD K.K, Tokyo, Japan.
Shimamoto T; MSD K.K, Tokyo, Japan.
Suzuki K; Japanese Red Cross Medical Center, Tokyo, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Nov; Vol. 112 (5), pp. 640-649. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Journal Article
MeSH Terms :
Randomized Controlled Trials as Topic*
Risk Assessment*
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dexamethasone/*administration & dosage
Lenalidomide/*administration & dosage
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Asian Continental Ancestry Group ; Biosimilar Pharmaceuticals ; Disease-Free Survival ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Multiple Myeloma/mortality
Czasopismo naukowe
Tytuł :
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols.
Autorzy :
Popov A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. .
Buldini B; Dipartimento di Salute della Donna e del Bambino, University of Padua, Padua, Italy.
De Lorenzo P; Interfant Trial Data Center, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.; Tettamanti Research Center, Pediatric Clinic, University of Milan-Bicocca, Fondazione MBBM/ S. Gerardo Hospital Monza, Monza, Italy.
Disarò S; Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy.
Verzhbitskaya T; Regional Children Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
Movchan L; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
Giarin E; Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy.
Shorikov E; PET-Technology Center of Nuclear Medicine, Ekaterinburg, Russian Federation.
Di Meglio A; Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy.
Tsaur G; Regional Children Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
Parasole R; Department of Pediatric Hemato-Oncology, Santobono-Pausilipon Hospital, Naples, Italy.
Miakova N; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Boichenko E; City Children's Hospital №1, Saint-Petersburg, Russian Federation.
Kondratchik K; Morozov Children's Hospital, Moscow, Russian Federation.
Aleinikova O; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
Karachunskiy A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Roumiantsev A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Locatelli F; Department of Pediatric Hematology and Oncology, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.; Sapienza, University of Rome, Rome, Italy.
Biondi A; Tettamanti Research Center, Pediatric Clinic, University of Milan-Bicocca, Fondazione MBBM/ S. Gerardo Hospital Monza, Monza, Italy.
Pieters R; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Valsecchi MG; Interfant Trial Data Center, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
Fechina L; Regional Children Hospital, Ekaterinburg, Russian Federation.; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
Basso G; Dipartimento di Salute della Donna e del Bambino, University of Padua, Padua, Italy.; Italian Institute for Genomic Medicine, Turin, Italy.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 3042-3046. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Flow Cytometry*/methods
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasm, Residual/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bone Marrow/pathology ; Female ; Humans ; Incidence ; Infant ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Prognosis ; Recurrence ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Autorzy :
Li J; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Bao L; Department of Hematology, Beijing Jishuitan Hospital, Beijing, China.
Xia Z; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wang S; The First Affiliated Hospital of Xiamen University, Xiamen, China.
Zhou X; Wuxi People Hospital, WuXi, China.
Ding K; Anhui Provincial Cancer Hospital, Hefei, China.
Zhang W; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yang W; Shengjing Hospital of China Medical University, Shengjing, China.
Li B; The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Fu C; Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
Chen B; Department of Hematology, The Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.
Hua L; The Affiliated Hospital of Hebei University, Baoding, China.
Wang L; Department of Hematology, ZhuJiang Hospital of Southern Medical Univeristy, Guangzhou, China.
Luo J; The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yang Y; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Xu T; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Wang W; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Huang Y; The First Affiliated Hospital of Xiamen University, Xiamen, China.
Wu G; Anhui Provincial Cancer Hospital, Hefei, China.
Liu P; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2589-2598. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Boron Compounds/*administration & dosage
Glycine/*analogs & derivatives
Multiple Myeloma/*drug therapy
Peripheral Nervous System Diseases/*chemically induced
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boron Compounds/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Administration Schedule ; Female ; Glycine/administration & dosage ; Glycine/adverse effects ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Staging ; Peripheral Nervous System Diseases/diagnosis ; Peripheral Nervous System Diseases/physiopathology ; Remission Induction ; Survival Analysis ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Autorzy :
Díaz-Santa J; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Rodríguez-Romanos R; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Osca G; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Pratcorona M; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Garrido A; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Coll R; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Moret C; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Escoda L; Hematology Department, Catalan Institute of Oncology (ICO), Hospital Joan XXIII, Tarragona, Spain.
Tormo M; Hematology Department, Hospital Clínico, Valencia, Spain.
Heras I; Department of Hematology, University Hospital Morales Meseguer, Murcia, Spain.
Arnan M; Department of Hematology, Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain.
Vives S; Hematology Department, Catalan Institute of Oncology (ICO), Badalona, Josep Carreras Leukemia Research Institute (IJC), Badalona, Barcelona, Spain.
Salamero O; Hematology Department, Hospital Vall d'Hebró, Barcelona, Spain.
Lloveras N; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Bargay J; Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca, Spain.
Sampol A; Hematology Department, Hospital Son Espases, Palma de Mallorca, Spain.
Cruz D; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Garcia A; Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain.
Quiñones T; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain.
Esteve J; Hematology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Gallardo D; Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain. .
Pokaż więcej
Corporate Authors :
on the behalf of CETLAM Group
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2925-2933. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genotype*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Glucuronosyltransferase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Alleles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers, Tumor ; Cause of Death ; Cytarabine/administration & dosage ; Female ; Humans ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Prognosis ; Proportional Hazards Models ; Recurrence ; Remission Induction ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
Autorzy :
Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bose P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naqvi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kornblau SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; Georgia Cancer Center, Augusta University, Augusta, GA, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2914-2924. Date of Electronic Publication: 2020 Jun 16.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cytarabine/*administration & dosage
Daunorubicin/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers ; Biomarkers, Tumor ; Cytarabine/adverse effects ; Daunorubicin/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/etiology ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Remission Induction ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis.
Autorzy :
Li X; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.
Zheng H; Department of Neurology, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, 430063, Hubei, People's Republic of China.
Yu MC; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China. .
Wang W; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.
Wu XH; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.
Yang DM; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.
Xu J; Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5085-5097. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Breast Neoplasms/*drug therapy
Granulocyte Colony-Stimulating Factor/*administration & dosage
Neutropenia/*drug therapy
Polyethylene Glycols/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/blood ; Chemotherapy-Induced Febrile Neutropenia/drug therapy ; Female ; Humans ; Neutropenia/chemically induced ; Quality of Life ; Randomized Controlled Trials as Topic ; Recombinant Proteins/administration & dosage
Czasopismo naukowe
Tytuł :
FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Autorzy :
Kumamoto T; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. .
Goto H; Department of Hematology and Oncology, Children's Cancer Center, Kanagawa Children's Medical Center, Yokohama, Japan.
Ogawa C; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hori T; Department of Pediatrics, Aich Medical University Hospital, Nagoya, Japan.
Deguchi T; Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Araki T; Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Manabe A; Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Horibe K; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Toyoda H; Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Nov; Vol. 112 (5), pp. 720-724. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Arabinonucleosides/administration & dosage ; Arabinonucleosides/adverse effects ; Child ; Child, Preschool ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Febrile Neutropenia/chemically induced ; Female ; Humans ; Infant ; Japan ; Male ; Recurrence ; Safety ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma.
Autorzy :
Mitsunaga S; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. .; Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan. .
Kasamatsu E; Medical Affairs Department, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Machii K; Medical Affairs Department, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5271-5279. Date of Electronic Publication: 2020 Feb 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cachexia/*epidemiology
Carcinoma, Pancreatic Ductal/*drug therapy
Carcinoma, Pancreatic Ductal/*epidemiology
Pancreatic Neoplasms/*drug therapy
Pancreatic Neoplasms/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Body Mass Index ; Cachexia/diagnosis ; Cachexia/etiology ; Carcinoma, Pancreatic Ductal/complications ; Carcinoma, Pancreatic Ductal/pathology ; Disease Progression ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Pancreatic Neoplasms/complications ; Pancreatic Neoplasms/pathology ; Prevalence ; Prognosis ; Quality of Life ; Retrospective Studies ; Survival Analysis ; Weight Loss/drug effects
Czasopismo naukowe
Tytuł :
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Autorzy :
Le Gouill S; Service d'hématologie clinique, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France. Electronic address: .
Beldi-Ferchiou A; Biological Haematology and Immunology Department, Groupe Hospitalier Mondor, Assistance Publique Hôpitaux de Paris, INSERM U955, Paris, France.
Alcantara M; Onco-Haematology, Université de Paris, Hôpital and Institut Necker-Enfants Malades, Assistance-Publique-Hôpitaux de Paris, INSERM U1151, Paris, France.
Cacheux V; Service d'hématologie clinique du CHU de Clermont-Ferrand, Clermont-Ferrand, France.
Safar V; Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Burroni B; Department of Pathology, Cochin Hospital, Paris, France.
Guidez S; Service d'hématologie clinique du CHU de Poitiers, Poitiers, France.
Gastinne T; Service d'hématologie clinique, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.
Canioni D; Onco-Haematology, Université de Paris, Hôpital and Institut Necker-Enfants Malades, Assistance-Publique-Hôpitaux de Paris, INSERM U1151, Paris, France.
Thieblemont C; Service d'hémato-oncologie, L'hôpital Saint-Louis AP-HP, Université de Paris, Paris, France.
Maisonneuve H; CHD de Vendée, La Roche-Sur-Yon, France.
Bodet-Milin C; Service de médecine nucléaire, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.
Houot R; Service d'Hématologie Clinique, CHU de Rennes, Université de Rennes, INSERM U1236, Rennes, France.
Oberic L; Service d'hématologie, IUC Toulouse Oncopole, Toulouse, France.
Bouabdallah K; Service d'Hématologie, CHU Bordeaux, Bordeaux, France.
Bescond C; Service d'Hématologie, CHU Angers, Angers, France.
Damaj G; Haematology Institute, Normandy University School of Medicine, Caen, France.
Jaccard A; CHU de Limoges, Limoges, France.
Daguindau N; Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy, France.
Moreau A; Service d'anatomo-pathologie, CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.
Tilly H; Département d'Hématologie and U1245, Centre Henri Becquerel, Université de Rouen, Rouen, France.
Ribrag V; Département des Innovations Thérapeutiques et Essais Précoces, Université Paris-Saclay, Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Paris, France.
Delfau-Larue MH; Biological Haematology and Immunology Department, Groupe Hospitalier Mondor, Assistance Publique Hôpitaux de Paris, INSERM U955, Paris, France.
Hermine O; Department of Adult Haematology, Université de Paris, Hôpital Necker-Enfants Malades, Assistance-Publique, Hôpitaux de Paris, Imagine Institute, INSERM U1153, Paris, France.
Macintyre E; Onco-Haematology, Université de Paris, Hôpital and Institut Necker-Enfants Malades, Assistance-Publique-Hôpitaux de Paris, INSERM U1151, Paris, France.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Nov; Vol. 7 (11), pp. e798-e807. Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cytarabine/*administration & dosage
Lymphoma, Mantle-Cell/*drug therapy
Adolescent ; Adult ; Anemia/etiology ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Area Under Curve ; Bone Marrow/pathology ; Cytarabine/adverse effects ; Dexamethasone/administration & dosage ; Humans ; Lymphoma, Mantle-Cell/pathology ; Lymphoma, Mantle-Cell/therapy ; Middle Aged ; Neoplasm, Residual ; Prospective Studies ; ROC Curve ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies